Eli Lilly to launch knowledge on the retatrutide weight reduction remedy in 2025

The Eli Lilly & Co. logo in the Digital Health Innovation Hub facility of the company in Singapore, on Thursday, November 14, 2024.

Erz huiying | Bloomberg | Getty pictures

Eli Lilly On Thursday, data from a study in the late stage to publish his weight loss drug Retatrutid of the next generation a few months earlier than expected this year.

The company expects to deliver results from a 68-week study to people with obesity and osteoarthritis of the knee in 2025. Eli Lilly previously said that the third phase study was expected to be completed in February 2026.

It is one of the at least nine clinical studies with retatrutide that work differently than the treatments of obesity and diabetes on the market and seems to be even more effective if we lose weight.

“We believe that this potential new medication can provide even more weight loss than Tirepatide and may offer additional health benefits,” said Daniel Skovronsky, Chief Scientific and Medical Officer from Lilly, during a win on Thursday.

Retatrutid is an essential part of Eli Lilly's pharmaceutical pipeline, which could help the company Novo Nordisk.

Retatrutide works as a “triple G” drare and ahmt three hunger regulating hormones after: GLP -1, GIP and glucagon. This seems to have more impact on the appetite and satisfaction of a person with food than on other treatments.

Tirepatid, the active ingredient in Eli Lilly's weight loss shot zepbound and diabetes drug Mounjaro, imitates two of the hormones, GLP-1 and gip. Novo Nordisk's weight loss medication Wegovy only adds GLP-1.

Retatrutide seems to cause an even greater weight loss than Tirzatide, which has risen into demand in the United States

Retatrutid helped the patient to lose 24.2% of their body weight or £ 58 after 48 weeks in a middle of the stage in adults who were obese or overweight. Those who took the placebo lost 2.1% of their body weight after the same time.

Higher doses of Tirzidatide helped patients with obesity on average up to 22.5% of their body weight in studies in the late stage.

– Angelica Peebles from CNBC contributed to this report.